New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2013
16:02 EDTLCILannett reports Q2 EPS 10c, consensus 5c
Reports Q2 revenue $36.6M, consensus $33.53M.
News For LCI From The Last 14 Days
Check below for free stories on LCI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2014
18:38 EDTLCIOn The Fly: After Hours Movers
Subscribe for More Information
15:44 EDTLCILannett sees FY15 sales $350M-$370M, consensus $349.6M
Subscribe for More Information
15:43 EDTLCILannett reports Q4 EPS 64c, consensus 58c
Reports Q4 revenue $80.6M, consensus $79.06M.
15:27 EDTLCINotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Workday (WDAY), consensus (14c); Williams-Sonoma (WSM), consensus 53c; Bally Technologies (BYI), consensus $1.22; Guess (GES), consensus 29c; Lannett (LCI), consensus 58c; Greif (GEF), consensus 84c.
August 20, 2014
11:35 EDTLCILannett expects to launch Estradiol tablets within the next several months
Lannett Company announced that it has agreed to purchase ANDAs for Estradiol Tablets, USP, 0.5 mg, 1 mg and 2 mg, and Selegiline Hydrochloride Capsules 5 mg, upon the completion of a successful technical transfer. The company did not disclose the name of the seller nor the financial terms of the transaction. Lannett expects to launch Estradiol Tablets within the next several months and Selegiline Hydrochloride Capsules sometime thereafter. According to IMS, for the full year 2013 total sales of Estradiol Tablets, USP, 0.5 mg, 1 mg and 2 mg, and Selegiline Hydrochloride Capsules 5 mg at Average Wholesale Price were approximately $31M and $8.5M, respectively. The reference listed drug manufacturer for Estradiol Tablets is Barr Laboratories; Selegiline Hydrochloride Capsules 5 mg is the generic equivalent of Somerset Pharmaceuticals, Inc.’s Eldepryl. “We are pleased to add Estradiol Tablets and Selegiline Hydrochloride Capsules to our offering,” said Arthur Bedrosian, president and chief executive officer of Lannett. “The acquisition of these two important medications further expands and diversifies our product portfolio and complements our internal research and development efforts.”
10:08 EDTLCILannett does not expect study to significantly impact Digoxin sales
Subscribe for More Information
07:56 EDTLCILannett digoxen use in clinics unlikely to change, says Canaccord
Canaccord said the use of Lannett's digoxen drug was only prescribed to critically ill Afib patients so the mortality risk cited in a retrospective study by Turakhia is not surprising. Given the risk of thrombotic events from Afib progression far outweighing the mortality risk the firm sees little change to clinical practice. Shares of Lannett are Buy rated with a $55 price target.
August 19, 2014
12:26 EDTLCILannett downgraded to Hold from Buy at Craig-Hallum
Subscribe for More Information
09:47 EDTLCILannett could see decreased digoxin sales, says Craig-Hallum
Subscribe for More Information
August 18, 2014
16:52 EDTLCIOn The Fly: Closing Wrap
Subscribe for More Information
12:18 EDTLCIThe Fly: Midday Wrap
The market opened in positive territory following news that Russia and Ukraine were working on a potential ceasefire. The market had faltered on Friday following reports that the Ukraine army had attacked a Russian military vehicle after it crossed into Ukraine territory. The market opened sharply higher and then received an additional boost when the NAHB Housing market Index came in above expectations. The averages quickly moved to session highs, lifting the S&P to its highest level ever and putting August on track for the best monthly performance since February. ECONOMIC EVENTS: The NAHB homebuilder sentiment index rose 2 points to 55 in August. The index had climbed 4 points to 53 in July. This is the highest level since January's 56. The single family sales index edged up to 58 from 56 (revised from 57). The future index was 65 from 63 (revised from 64). The index of prospective buyer traffic improved to 42 from 39 (revised from 39). Data was better than expected. COMPANY NEWS: Shares of discount retailer Dollar General (DG) were higher by about 10% after the company announced a proposal to acquire rival Family Dollar (FDO) for $78.50 per share in cash, in a transaction valued at $9.7B. Shares of Family Dollar rose approximately 5% on the news. MAJOR MOVERS: Among the notable gainers was Sensata Technologies (ST), which rose 5.6% after after agreeing to buy privately held Schrader International for $1B. Also higher was Lannett (LCI), which gained 9.3% after the company said fourth quarter and full-year 2014 earnings per share and revenue would exceed analysts' consensus estimates. Among the noteworthy losers was Monster Beverage (MNST), which fell about 4% after research firm Jefferies downgraded the shares to Hold from Buy saying the valuation looks full following its recent rally. Also lower was NXP Semiconductors (NXPI), which dropped 2.3% after Goldman Sachs downgraded the company to Sell from Neutral, and downgraded the semiconductor sector to Cautious from Neutral. The firm expects consensus estimates to move lower due to cyclical headwinds, increased Q4 and Q1 seasonality, and a RF correction. Goldman lowered their price target on the shares to $54 from $58. INDEXES: Near midday, the Dow was up 168.13, or 1.01%, to 16,831.04, the Nasdaq rose 44.11, or 0.99%, to 4,508.87, and the S&P 500 was higher by 16.79, or 0.86%, to 1,971.88.
10:43 EDTLCIHigh option volume stocks
Subscribe for More Information
10:06 EDTLCILannett surges after upbeat Q4, FY14 outlook
Subscribe for More Information
09:03 EDTLCIOn The Fly: Pre-market Movers
Subscribe for More Information
07:30 EDTLCILannett sees FY14 adjusted EPS $1.94-$1.98, consensus $1.75
Sees FY14 revenue $274M, consensus $264.32M.
07:28 EDTLCILannett sees FY14 results 'far exceeding' prior year
Subscribe for More Information
07:28 EDTLCILannett sees Q4 EPS 60c-64c, consensus 41c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use